L. Kappos, D. Bates, and G. Edan, Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring, The Lancet Neurology, vol.10, issue.8, pp.745-758, 2011.
DOI : 10.1016/S1474-4422(11)70149-1

O. Connor, P. Goodman, A. Kappos, and L. , Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis, Neurology, vol.76, issue.22, pp.1858-1865, 2011.
DOI : 10.1212/WNL.0b013e31821e7c8a

J. Killestein, A. Vennegoor, and E. Strijbis, Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated, Annals of Neurology, vol.72, issue.suppl 9, pp.392-395, 2010.
DOI : 10.1002/ana.22074

T. West and B. Cree, Natalizumab dosage suspension: Are we helping or hurting?, Annals of Neurology, vol.68, issue.13 pt 2, pp.395-399
DOI : 10.1002/ana.22163

C. Polman, S. Reingold, and G. Edan, Diagnostic criteria for multiple sclerosis: 2005 revisions to the ???McDonald Criteria???, Annals of Neurology, vol.6, issue.6, pp.840-846, 2005.
DOI : 10.1002/ana.20703

B. Moraal, I. Van-den-elskamp, and D. Knol, Long-interval T2-weighted subtraction magnetic resonance imaging: A powerful new outcome measure in multiple sclerosis trials, Ann Neurol, vol.67, pp.667-675, 2010.

B. Khatri, S. Man, and G. Giovannoni, Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function, Neurology, vol.72, issue.5, pp.402-409, 2009.
DOI : 10.1212/01.wnl.0000341766.59028.9d

J. Havla, L. Gerdes, and I. Meinl, De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate, Journal of Neurology, vol.63, issue.10, pp.1665-1669, 2011.
DOI : 10.1007/s00415-011-5996-y

M. Vellinga, J. Castelijns, and F. Barkhof, POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS, Neurology, vol.70, issue.Issue 13, Part 2, pp.1150-1151, 2008.
DOI : 10.1212/01.wnl.0000265393.03231.e5

R. Fox and L. Kappos, Is natalizumab overshooting its rebound? Neurol, pp.1173-1174, 2008.

R. Fox, L. Kappos, and B. Cree, Effects of a 24-week natalizumab treatment interruption on clinical and radiological parameters of multiple sclerosis disease activity: the RESTORE study, Mult Scler J, issue.S10, pp.17-509, 2011.

S. Rossi, C. Motta, and V. Studer, Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab, European Journal of Neurology, vol.72, issue.1, pp.87-94
DOI : 10.1111/j.1468-1331.2012.03794.x

M. Magraner, F. Coret, and A. Navarré, Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study, Journal of Neurology, vol.16, issue.9, pp.2581805-1811, 2011.
DOI : 10.1007/s00415-011-6019-8

G. Comi, M. Filippi, and J. Wolinsky, European/Canadian multicenter, doubleblind , randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis, Annal Neurol, vol.49, pp.270-277, 2001.

C. Polman, O. Connor, P. Havrdova, and E. , A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis, New England Journal of Medicine, vol.354, issue.9, pp.899-910, 2006.
DOI : 10.1056/NEJMoa044397

. Gobbi, Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial, BMC Neurology, vol.354, issue.10, p.101, 2013.
DOI : 10.1056/NEJMoa044397
URL : https://hal.archives-ouvertes.fr/inserm-00850833